Ganciclovir phrophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients

Transplantation Proceedings

Volumn 36, Issue 10, 2004, Pages 3019-3024

  Israni, A ^a   Krok, K ^a   Cohen, D ^a   Blumberg, E ^a   Bloom, Roy D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LEUKOCYTE COUNT; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; ADULT; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; DEMOGRAPHY; FEMALE; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TIME; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 21244500603     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.10.091     Document Type: Article

References (20)

1. Brennan D: Cytomegalovirus in renal transplantation. J Am Soc Neph 12:848, 2001
2. Schnitzler M, Woodward R, Brennan D, et al: The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. Amer J Kid Dis 29:428, 1997
3. Rubin R: Clinical approach to infection in the compromised host. In. Rubin RH, Young (eds): LSInfection in the Organ Transplant Patient. New York: Plenum; 1994, p 629
4. Rubin R: Infectious disease complications of renal transplantation. Kidney Int 44:221, 1993
5. Jassal S, Roscoe J, Zaltzman J, et al: Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Neph 9:1697, 1998
6. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, et al: Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70:1174, 2000
7. Brennan D, Garlock K, Singer G, et al: Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64:1843, 1997
8. Fishman J, Doran M, Volpicelli S, et al: Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 69:389, 2000
9. Balfour H, Chace B, Stapleton J, et al: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320:1381, 1989
10. Lowance D, Neumayer H, Legendre C, et al: Valacyclovir for the prevention of cytomegaloviras disease after renal transplantation. N Engl J Med 340:1462, 1999
11. Snydman D, Werner B, Heinze-Lacey B, et al: Use of cytomegalovirus immune globulin to prevent cytomegaloviras disease in renal transplant recipients. N Engl J Med 317:1049, 1987
12. Couchoud C: Cytomegalovirus phrophylaxis with antiviral agents for solid organ transplantation. Cochrane Library 2000(4)
13. STATA 8.0 (computer program). Version. College Station, Texas; 2003
14. Fishman J, Rubin R: Infection in organ-transplant recipients. N Engl J Med 338:1741, 1998
15. Becker B, Becker Y, Leverson G, et al: Reassessing the impact of cytomegalovirus infection in kidney and kidney-transplantation. AJKD 39:1088, 2002
16. Mestre M, Bas J, Alsina J, et al: Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 31:2254, 1999
17. Muller T, Grebe S, Neumann M, et al: Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 64:1432, 1997
18. Martins L, Ventura A, Dias L, et al: Long-term effects of ATG therapy on lymphocyte subsets. Transplant Proc 33:2186, 2001
19. Limaye A, Corey L, Koelle D, et al: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645, 2000
20. Limaye A, Raghu G, Koelle D, et al: High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. Journal of Infectious Diseases 185:20, 2002